|
|
|
13.05.26 - 16:01
|
AstraZeneca Buy (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca auf "Buy" mit einem Kursziel von 18000 Pence belassen. Michael Leuchten attestierte dem Pharmakonzern in einer am Mittwoch vorliegenden Studie einen attraktiven ......
|
|
|
13.05.26 - 12:48
|
UAE approves AstraZeneca′s Baxfendy for hypertension (PBR)
|
|
|
With this authorisation, the UAE is said to become the first nation worldwide to approve this treatment, which is offered in 1mg and 2mg doses. This move underscores
The post UAE approves AstraZeneca's Baxfendy for hypertension appeared first on Pharmaceutical Business review....
|
|
|
13.05.26 - 07:06
|
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results (Business Wire)
|
|
|
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures
IPH4502 (Nectin-4 ADC) continues to show preliminary anti-tumor activity with favorable safety profile to date; the maximum tolerated dose has been reached and enrollment in the Phase 1 dose escalation and cohort enrichment is nearing completion
PACIFIC-9 Phase 3 trial, which includes monalizumab and is led by AstraZeneca, continues to advance toward a planned H2 2026 data readout
IPH5201 (anti-CD39 antibody), developed in collaboration with AstraZeneca, showed encouraging early results presented in a Clinical Trials Plenary Session at AACR 2026, supporting continued investigation in the MATISSE Phase 2 study in non-small cell lung cancer (NSCLC)
Cash position of €25.4 million1 as of March 31, 2026, with an anticipated cash runway until the end of Q3 2026
Con...
|
|
|
|
|
|
|
|
|
|
|
04.05.26 - 08:18
|
AstraZeneca Outperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat das Kursziel für Astrazeneca von 20500 auf 18600 Pence gesenkt und die Einstufung auf "Outperform" belassen. Justin Smith begründete die Zielsenkung in einer am Montag vorliegenden ......
|
|
|
|
|
01.05.26 - 16:00
|
Total Voting Rights and Admission of Shares (Cision)
|
|
|
1 May 2026
Total Voting Rights and Notification of Admission of Further Securities to Trading (PRM 1.6.4R)
Total Voting Rights
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 April 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,550,995,630 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,995,630.
The above figure for the total number of voting rights may be used by shareholders as...
|
|
|
01.05.26 - 12:27
|
MÄRKTE EUROPA/Verluste in London - AstraZeneca belasten (Dow Jones)
|
|
|
DOW JONES--Der Aktienhandel in Europa beschränkt sich 1. Mai auf den Handelsplatz London, wo der der werktätigen Bevölkerung gewidmete Feiertag immer auf den ersten Monat nach dem 1. Mai fällt. Die britischen Aktien notierten am Freitag in einem dünnen ......
|
|
|
|
|
|
|
|
|
|
|
01.05.26 - 08:09
|
AstraZeneca Buy (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca auf "Buy" mit einem Kursziel von 18000 Pence belassen. Die Empfehlung eines US-Beratergremiums, das Medikament Camizestrant für eine spezielle Anwendung nicht zuzulassen, ......
|
|
|
01.05.26 - 08:06
|
FDA ODAC vote on camizestrant in breast cancer (Cision)
|
|
|
01 May 2026
Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer
The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation,...
|
|
|
|
|
30.04.26 - 21:36
|
AstraZeneca Overweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Astrazeneca auf "Overweight" mit einem Kursziel von 16000 Pence belassen. Die Empfehlung eines US-Beratergremiums, das Medikament Camizestrant für eine spezielle Anwendung nicht ......
|
|
|
30.04.26 - 20:30
|
AstraZeneca Is a Buy as More Than 20 Phase III Readouts Loom (24/7 Wall St.)
|
|
|
Our AstraZeneca (NASDAQ:AZN) call comes one day after the British drugmaker reported Q1 2026 revenue of $15.29 billion, up 13% year over year, and reaffirmed full-year guidance. With shares at $185.20, the stock has cooled from its 52-week high of $210.50. Our 24/7 Wall St. price target for AstraZeneca is $227.39, implying 22.78% upside over ... AstraZeneca Is a Buy as More Than 20 Phase III Readouts Loom...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
